Pharmaceutical giant Novo Nordisk said on Tuesday it would invest millions in Iran, joining a still very small group of European companies to have announced concrete deals in Tehran after it struck a deal on its nuclear program.
Novo Nordisk, the world’s largest diabetes drugs maker, said it would build a €70 million ($78 million) manufacturing plant in Iran. It already has a subsidiary in the country selling insulin and employing 130 people there since 2005, Reuters reported.
